Terminated PHASE2 INTERVENTIONAL 1-arm NCT00402896

Malignant Pleural Effusion With ZD6474

Treatment of Malignant Pleural Effusion With ZD6474, a Novel Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor

Sponsor: AstraZeneca

Conditions Lung Cancer Pleural Effusion

Interventions ZD6474

Updated 8 times since 2017 Last updated: Feb 11, 2016 Started: Oct 31, 2006 Primary completion: Jun 30, 2014 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow Accrual

Other terminated trials from AstraZeneca

See all terminations from AstraZeneca

Other Lung Cancer trials with similar outcome

Browse all Lung Cancer trials

Listed as NCT00402896, this PHASE2 trial focuses on Lung Cancer and Pleural Effusion and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 8 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
M.D. Anderson Cancer Center
United States Department of Defense

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States